Please login to the form below

Not currently logged in
Email:
Password:

MRSA

This page shows the latest MRSA news and features for those working in and with pharma, biotech and healthcare.

Motif Bio preps US filing after antibiotic clears phase III

Motif Bio preps US filing after antibiotic clears phase III

resistance to other antibiotics, including ‘superbugs’such as methicillin resistant Staphylococcus aureus (MRSA).

Latest news

  • CHMP backs AZ's 'superbug' antibiotic product CHMP backs AZ's 'superbug' antibiotic product

    In 2011 AZ launched novel cephalosporin Zinforo (ceftaroline fosamil), the first drug in the class to be approved with data showing it could tackle the superbug methicillin-resistant Staphylococcus aureus (MRSA).

  • Pfizer takes MRSA vaccine into phase IIb trial Pfizer takes MRSA vaccine into phase IIb trial

    Pfizer takes MRSA vaccine into phase IIb trial. Trial will involve patients undergoing elective spinal fusion surgery. ... Pfizer has started enrolling patients into a mid-stage trial of its candidate vaccine for 'superbug' methicillin-resistant

  • Basilea’s novel antibiotic reaches UK market Basilea’s novel antibiotic reaches UK market

    Basilea’ s novel antibiotic reaches UK market. Zevtera can be used against a range of infections including MRSA. ... Treatment failure rates in pneumonia, especially pneumonia caused by MRSA are still high and have been attributed in part to inadequate

  • Cubist gets green light from FDA for new antibiotic Sivextro Cubist gets green light from FDA for new antibiotic Sivextro

    Sivextro is in the oxazolidinone class of antibiotics has been approved to treat ABSSSIs caused by certain Gram-positive bacteria, including 'superbug' methicillin-resistant Staphylococcus aureus (MRSA), and is available in ... Until the approval of

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    In November 2013, it won priority review from the US FDA for acute bacterial SSSIs caused by susceptible Gram-positive bacteria (including MRSA). ... Dalbavancin has an improved dosing regimen and increased potency versus vancomycin against Gram-positive

More from news
Approximately 4 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • Another lost decade for research? Another lost decade for research?

    the past five years), along with MRSA (eight filings) and HIV (nine filings).

  • Curbing the rise of drug resistance Curbing the rise of drug resistance

    Focusing on three bacteria and three diseases – Staphylococcus aureus (responsible for MRSA), E. ... These projected figures could be considerably worse if resistant bugs, such as MRSA that are making routine medical procedures far more perilous, are

  • Pharma deals during December 2014 Pharma deals during December 2014

    Cubicin is also approved for the treatment of bacteraemia caused by MRSA and methicillin-susceptible Staphylococcus aureus (MSSA). ... Approved in 2014, tedizolid phosphate ( Sivextro) is for the treatment of adult acute bacterial skin and skin structure

  • Pharma deals during July 2013 Pharma deals during July 2013

    infections, including methicillin-resistant Staphylococcus aureus (MRSA).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics